MX2022014768A - Anticuerpo multiespecifico. - Google Patents
Anticuerpo multiespecifico.Info
- Publication number
- MX2022014768A MX2022014768A MX2022014768A MX2022014768A MX2022014768A MX 2022014768 A MX2022014768 A MX 2022014768A MX 2022014768 A MX2022014768 A MX 2022014768A MX 2022014768 A MX2022014768 A MX 2022014768A MX 2022014768 A MX2022014768 A MX 2022014768A
- Authority
- MX
- Mexico
- Prior art keywords
- multispecific antibody
- antibody
- msln
- nucleic acid
- acid sequence
- Prior art date
Links
- 102000003735 Mesothelin Human genes 0.000 abstract 3
- 108090000015 Mesothelin Proteins 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a un anticuerpo multiespecífico que comprende dos dominios de unión basados en anticuerpo, que se unen específicamente a mesotelina (MSLN-BD); y al menos un dominio de unión basado en anticuerpo, que se une específicamente a CD3 (CD3-BD); en donde dicho anticuerpo multiespecífico no comprende un polipéptido de la región Fc de inmunoglobulina, y en donde cada uno de dichos MSLN-BD se une a mesotelina (MSLN) con una constante de disociación monovalente (KD) en el intervalo desde 0,5 hasta 20 nM, cuando se mide por SPR. La presente invención se refiere adicionalmente a secuencia(s) de ácidos nucleicos que codifica(n) dicho anticuerpo multiespecífico, vector(es) que comprende(n) dicha(s) secuencia(s) de ácidos nucleicos, célula(s) huésped que comprende(n) dicha(s) secuencia(s) de ácidos nucleicos o dicho(s) vector(es), y un procedimiento para producir dicho anticuerpo multiespecífico. Adicionalmente, la presente invención se refiere a composiciones farmacéuticas que comprenden dicho anticuerpo multiespecífico y procedimientos de uso de las mismas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20177337.1A EP3915580A1 (en) | 2020-05-29 | 2020-05-29 | Multispecific antibody |
PCT/EP2021/064427 WO2021239987A1 (en) | 2020-05-29 | 2021-05-28 | Multispecific antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022014768A true MX2022014768A (es) | 2023-01-11 |
Family
ID=84492160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022014768A MX2022014768A (es) | 2020-05-29 | 2021-05-28 | Anticuerpo multiespecifico. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230203162A1 (es) |
EP (1) | EP4157352A1 (es) |
JP (1) | JP2023526976A (es) |
KR (1) | KR20230018397A (es) |
CN (1) | CN116134052A (es) |
AU (1) | AU2021278317A1 (es) |
BR (1) | BR112022024161A2 (es) |
CA (1) | CA3184899A1 (es) |
IL (1) | IL298076A (es) |
MX (1) | MX2022014768A (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7247110B2 (ja) * | 2017-06-05 | 2023-03-28 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗cd3抗体 |
-
2021
- 2021-05-28 US US18/000,141 patent/US20230203162A1/en active Pending
- 2021-05-28 AU AU2021278317A patent/AU2021278317A1/en active Pending
- 2021-05-28 IL IL298076A patent/IL298076A/en unknown
- 2021-05-28 MX MX2022014768A patent/MX2022014768A/es unknown
- 2021-05-28 CA CA3184899A patent/CA3184899A1/en active Pending
- 2021-05-28 CN CN202180058995.5A patent/CN116134052A/zh active Pending
- 2021-05-28 KR KR1020227043493A patent/KR20230018397A/ko active Search and Examination
- 2021-05-28 BR BR112022024161A patent/BR112022024161A2/pt unknown
- 2021-05-28 EP EP21729866.0A patent/EP4157352A1/en active Pending
- 2021-05-28 JP JP2022571782A patent/JP2023526976A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230203162A1 (en) | 2023-06-29 |
IL298076A (en) | 2023-01-01 |
AU2021278317A1 (en) | 2022-12-22 |
CN116134052A (zh) | 2023-05-16 |
KR20230018397A (ko) | 2023-02-07 |
EP4157352A1 (en) | 2023-04-05 |
JP2023526976A (ja) | 2023-06-26 |
CA3184899A1 (en) | 2021-12-02 |
BR112022024161A2 (pt) | 2023-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020511113A5 (es) | ||
CY1122627T1 (el) | Αντισωματα εναντι της ceacam6 και χρησεις αυτων | |
Štěpánová et al. | Capillary electrophoretic methods applied to the investigation of peptide complexes | |
JP2020124209A5 (es) | ||
RU2467016C2 (ru) | Антитела к il-22 человека и их применение | |
RU2015111708A (ru) | Способ получения и отбора молекул, включающих по меньшей мере две различные группировки и их применение | |
MX2023007533A (es) | Anticuerpos multiespecificos que tienen especificidad para il-4r e il-31. | |
MX2022000652A (es) | Anticuerpos contra claudina 18 y metodos de tratamiento del cancer. | |
JP2011502522A5 (es) | ||
MX2023009022A (es) | Anticuerpos multiespecificos con especificidad para ror1 y cd3. | |
JP2015502373A5 (es) | ||
IL177337A0 (en) | Less immunogenic binding molecules | |
MX2022014768A (es) | Anticuerpo multiespecifico. | |
MX2022011951A (es) | Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos. | |
RU2018137419A (ru) | Связывающиеся с cd38 и pd-l1 молекулы | |
MX2022010665A (es) | Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos. | |
JP2017538412A5 (es) | ||
Jiang et al. | Detection of cystatin C biomarker for clinical measurement of renal disease by developed ELISA diagnostic kits | |
MX2021014411A (es) | Biomoleculas radiomarcadas con 18f. | |
PE20232050A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
Mannar et al. | Altered receptor binding, antibody evasion and retention of T cell recognition by the SARS-CoV-2 XBB. 1.5 spike protein | |
WO2020238643A1 (zh) | PETx聚合物、制备方法以及三维荆棘状传感器界面 | |
Eguchi et al. | An epitope‐directed antibody affinity maturation system utilizing mammalian cell survival as readout | |
GB2596993A (en) | Antibodies to symmetrically dimethylated arginine analytes and use thereof | |
EP4019540A1 (en) | Method for improving affinity of antibody for antigen and use thereof |